MEG3 expression was decreased compared to healthy tissues in various brain cancers (pituitary adenomas, glioma and the majority of meningiomas and meningioma cell lines) [149,154], bladder, lung, renal, breast, cervix, colon and prostate cancers and haematological malignancies such as MM, AML or myelodysplastic syndromes. Here, MEG3 is linked to myelodysplastic syndrome.